GPT and non-small cell lung carcinoma: One patient with advanced NSCLC developed grade 3 ALT elevation, grade 3 AST elevation, and grade 1 pneumonitis simultaneously on day 42 and further developed grade 3 hyponatremia after termination of pembrolizumab (Shimizu et al., 2016).